Thr164Ile polymorphism of β2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy

Background: β2-adrenergic receptor Thr164Ile (threonine (Thr) is replaced by an isoleucine (Ile) at codon 164) polymorphism was postulated to contribute to lower exercise tolerance and poor prognosis in patients with congestive heart failure. However, heart failure is associated with several abnormalities of β receptor signalling, and underlying mechanisms are not clear. Objectives: To investigate whether Thr164Ile polymorphism negatively modulates myocardial contractile performance and is associated with adverse long-term prognosis of patients with congestive heart failure. Methods: Among 55 subjects, cardiac contractile response to the β2-adrenergic receptor agonist terbutaline was assessed from the peak myocardial velocity of systolic shortening (Sm) in 18 subjects with the Ile-164 variant and 37 matched controls. In total, 24 subjects had normal left ventricular (LV) function and 31 presented with congestive heart failure due to idiopathic dilated cardiomyopathy. Results: In patients with normal LV function, peak terbutaline-induced increase (Δ) in Sm was lower in subjects with the Ile-164 variant than in controls (Δ33% (4%) vs Δ56% (4%), p<0.01). In patients with heart failure, subjects with Ile-164 showed further severe reduction of β2-adrenergic-mediated increase in Sm as compared with controls with heart failure (Δ20% (5%) vs Δ39% (4%), p<0.05). Patients with heart failure with Ile-164 showed a severely blunted force–frequency relationship in response to agonist stimulation. At 2-years of follow-up, patients with heart failure with the Ile-164 variant showed higher incidence of adverse events than controls with heart failure (75% (6/8)] vs 30% (7/23), p<0.05). Conclusions: The β2-adrenergic Thr164Ile polymorphism directly modulates adrenergic-mediated cardiac responses in patients with normal and failing myocardium. Furthermore, blunted β2 adrenergic-mediated myocardial contractile response in patients with Ile-164 variant seems to adversely modulate the course of congestive heart failure.

[1]  Jinny Park,et al.  Human β2‐adrenergic receptor gene haplotypes and venodilation in vivo , 2005, Clinical pharmacology and therapeutics.

[2]  H. Bruck,et al.  Thr164Ile polymorphism of the human beta2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo. , 2003, American journal of physiology. Heart and circulatory physiology.

[3]  R. Kim,et al.  Beta2 adrenoceptor THR164ILE polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo , 2003, Pharmacogenetics.

[4]  Otto A. Smiseth,et al.  Quantification of Left Ventricular Systolic Function by Tissue Doppler Echocardiography: Added Value of Measuring Pre- and Postejection Velocities in Ischemic Myocardium , 2002, Circulation.

[5]  P. Insel,et al.  Blunted Cardiac Responses to Receptor Activation in Subjects With Thr164Ile &bgr;2-Adrenoceptors , 2001, Circulation.

[6]  G. Dorn,et al.  Polymorphisms of the β2-Adrenergic Receptor Determine Exercise Capacity in Patients With Heart Failure , 2000 .

[7]  R. Lefkowitz,et al.  Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart : prospects for molecular ventricular assistance. , 2000, Circulation.

[8]  E. Lakatta,et al.  Recent Advances in Cardiac b2-Adrenergic Signal Transduction , 1999 .

[9]  T. Wakatsuki,et al.  Evaluation of left ventricular contraction abnormalities in patients with dilated cardiomyopathy with the use of pulsed tissue Doppler imaging. , 1999, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[10]  R. Lefkowitz,et al.  Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. , 1999, The Journal of clinical investigation.

[11]  G. Dorn,et al.  Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice , 1999 .

[12]  E. Lakatta,et al.  beta2-adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart. , 1999, Circulation.

[13]  T. McIntosh,et al.  The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. , 1998, The Journal of clinical investigation.

[14]  M. Bristow.  Why does the myocardium fail? Insights from basic science , 1998, The Lancet.

[15]  R. Horton.  The Wakley Prize, 1998 , 1998, The Lancet.

[16]  R. Summers,et al.  Regulation of beta-adrenoceptors in a rat model of cardiac failure: effect of perindopril. , 1998, Journal of cardiovascular pharmacology.

[17]  S. Ito,et al.  Assessment of left ventricular systolic wall motion velocity with pulsed tissue Doppler imaging: comparison with peak dP/dt of the left ventricular pressure curve. , 1998, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[18]  D P Strum,et al.  Quantitative assessment of alterations in regional left ventricular contractility with color-coded tissue Doppler echocardiography. Comparison with sonomicrometry and pressure-volume relations. , 1997, Circulation.

[19]  S. Green,et al.  Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Mario J. Garcia,et al.  Myocardial wall velocity assessment by pulsed Doppler tissue imaging: characteristic findings in normal subjects. , 1996, American heart journal.

[21]  E. Lakatta,et al.  Response of Failing Canine and Human Heart Cells to β2-Adrenergic Stimulation , 1995 .

[22]  S. Vatner,et al.  Myocardial B-adrenergic receptor function during the development of pacing-induced heart failure , 1994 .

[23]  S. Green,et al.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.

[24]  E. Lakatta,et al.  Beta 2-adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation. , 1994, The Journal of biological chemistry.

[25]  J R Jansen,et al.  Computation of aortic flow from pressure in humans using a nonlinear, three-element model. , 1993, Journal of applied physiology.

[26]  S. Vatner,et al.  Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. , 1993, The Journal of clinical investigation.

[27]  M. Böhm,et al.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.

[28]  O. Brodde.  Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. , 1991, Pharmacological reviews.

[29]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[30]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[31]  K. E. Newhouse.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1986, The Yale Journal of Biology and Medicine.

[32]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.